With a powerful team of consultants and collaborators,Calder Biosciences is a vaccine immunogen design company currently developing novel RSV and universal Influenza subunit vaccines, both representing major market opportunities with mitigated clinical risk. Principals of the firm have found a new way to engineer vaccines, ensuring greater stability, prolonging their duration in the body and thereby enhancing protection. Using a natural chemical reaction known as di-tyrosine (DT) crosslinking, Calder is creating safe and potent vaccines against viruses. Principals of the firm have devised a new way to target di-tyrosine crosslinks within the structure of a protein - thereby to strengthen and lock into place the protein structures of viral vaccines - an approach that increases the stability and potency of antibody-antigen recognition and specificity.
